Medicare To Track Transfusions In Dialysis Patients To Ensure Appropriate ESA Use
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS proposes to monitor transfusions in patients with end-stage renal disease as a new Medicare quality measure aimed at ensuring erythropoiesis-stimulating agents like Amgen’s Epogen are not “underutilized.”
You may also be interested in...
ESAs And Transfusions In Dialysis Patients: Watching For The Tipping Point
A study from the U.S. Renal Data System contributes to concerns that decreasing use of erythropoiesis-stimulating agents like Amgen’s Epogen in dialysis patients can lead to a significant increase in the need for blood transfusions.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.